Proteome Sciences PLC LON:PRM has received notification from Vulpes Life Sciences Fund that on 10 May 2017 it purchased 97,314 ordinary shares of 1p each in the capital of the
Proteome Sciences plc LON:PRM has received notification from Vulpes Life Sciences Fund that on 02 May 2017 it purchased 100,000 ordinary shares of 1p each in the capital of the
Proteome Sciences’ Jeremy Haigh discusses their preliminary results out, the key drivers behind the 46% increase in revenues, their twin-prong strategy, personalised medicine and expectations for the rest of the year in this exclusive interview with DirectorsTalk
Proteome Sciences plc (LON:PRM) Chief Executive Officer Jeremy Haigh talks to DirectorsTalk about it’s positive year end results. With a 46% jump in revenues for last year, Jeremy explains what
Proteome Sciences plc has given DirectorsTalk its audited results for the year ended 31 December 2016. Highlights: — 46% revenue growth to GBP2.74m, underpinned by 57% increase in sales of
Proteome Sciences plc (LON:PRM) Chief Executive Officer Jeremy Haigh caught up with DirectorsTalk for an exclusive interview to discuss the latest trading update, the consolidation of their Frankfurt laboratory, the
Proteome Sciences plc (LON:PRM) CEO Jeremy Haigh talks to DirectorsTalk about its strong trading update issued today. Jeremy provides more background on the progress made throughout 2016, explains the consolidation
Jeremy Haigh, Chief Executive of Proteome Sciences LON:PRM, commented: “While we are satisfied with progress over the last year, there is much yet to do if we want to realise the
© 2025 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
